Table 1 Patient demographics

From: Individualized non-invasive deep brain stimulation of the basal ganglia using transcranial ultrasound stimulation

Characteristic

Range/Category

Sex

M (n = 9) / F (n = 1)

Age (years)

49–81

Disease Duration (years)

4–34

More Affected Side

Left (n = 5, PD), Right (n = 4, PD), Symmetric (n = 1, Dystonia)

Initial Symptoms

Tremor (n = 3, PD), Reduced Dexterity/Rigidity (n = 6, PD), Dystonic Posture (n = 1, Dystonia)

MDS-UPDRS Score (Med-ON)

13–58

LEDDa (mg)

1075–3520

  1. M male, n number of patients, F female, PD Parkinson’s Disease, MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale, LEDD levodopa equivalent daily dose.
  2. aCalculated using the following formula and conversion factors: Levodopa equivalent dose calculated as 100 mg of standard levodopa = 133 mg of controlled-release levodopa = 303 mg of entacapone = 100 mg of amantadine = 1 mg of pramipexole =100 mg rasagiline= 5 mg of ropinirole = 3.3 mg of rotigotine = 10 mg of selegiline.
Back to article page